Table 2.
Active Clinical Trials in FRDA
Agent | Agent | Status | Disease Stage | Clinical Trial Number |
---|---|---|---|---|
Vatiquinone (MOVE-FA) | PTC 743 | Phase II/III pivotal | Ambulatory Children | NCT04577352 |
CTI-1601 | Tat-frataxin | Phase I/II | Later ambulatory, non ambulatory adults | NCT04519567 |
NAD+ and Exercise in FRDA (ExRx in FA) | Nicotinamide riboside | Phase II | Ambulatory, early non ambulatory adults and children | NCT04192136 |
RT001 | Deuterated fatty acid | Phase II/III Pivotal trial | Ambulatory,early non ambulatory adults and children | NCT04102501 |
RTA 408 (MOXIe) | Omaveloxolone | Phase II/III Potentially Pivotal trial | Ambulatory,early non ambulatory adults and older children | NCT02255435 |
NAD+ precursor supplementation | Phase I/II | Later ambulatory, non ambulatory adults | NCT04817111 |